Explore standout human trials of semaglutide and tirzepatide, including outcomes in weight management, cardiovascular health, and chronic kidney disease.
Why successful trials have changed the conversation
Peptide medicine development is now supported by a series of major randomized clinical trials in metabolic disease. Unlike discussions built on cell cultures or animal experiments, these trials enrolled large groups of people, specified outcomes before treatment, and compared active medicines with control groups. The most compelling success stories have involved drugs acting on incretin pathways, including glucagon-like peptide-1, known as GLP-1, and glucose-dependent insulinotropic polypeptide, known as GIP. This collection focuses on encouraging, published results. It is a selective tour of successes rather than a complete survey of all clinical trials, and favorable efficacy findings should always be read alongside adverse-event and eligibility information.
STEP 1: a landmark semaglutide result
The STEP 1 trial enrolled 1,961 adults with overweight or obesity who did not have diabetes. Participants received semaglutide 2.4 mg once weekly or a placebo, both alongside lifestyle intervention, for 68 weeks. Published in the New England Journal of Medicine in 2021, the trial reported an average body-weight change of minus 14.9 percent in the semaglutide group compared with minus 2.4 percent in the placebo group. Those results drew attention because the size of the average change was substantially greater than was commonly associated with earlier nonsurgical medication approaches. The finding applies to the studied treatment, population, and circumstances, not to all products advertised as peptides.
SURMOUNT-1: the tirzepatide breakthrough
SURMOUNT-1 studied 2,539 adults with obesity, or overweight with a weight-related complication, without diabetes. The double-blind trial compared several tirzepatide dose groups with placebo over 72 weeks. In the published 2022 report, mean body-weight change was minus 15.0 percent, minus 19.5 percent, and minus 20.9 percent across the studied 5 mg, 10 mg, and 15 mg groups, compared with minus 3.1 percent for placebo. These were notable results from a medication that activates both GIP and GLP-1 receptors. They demonstrate that carefully designed peptide-based drugs can produce substantial measured outcomes in controlled settings. They do not establish that unregulated copies have equivalent quality or effects.
SELECT: cardiovascular outcomes beyond weight
A particularly important question is whether clinical benefits extend beyond a scale measurement. The SELECT trial followed people with established cardiovascular disease and overweight or obesity but without diabetes. The study examined whether semaglutide could reduce major adverse cardiovascular events. Published trial findings reported a lower incidence of the composite primary endpoint in the semaglutide group than in the placebo group, with events in 6.5 percent versus 8.0 percent of participants over the trial follow-up. Results like these matter because they measure clinically consequential events rather than relying only on biomarkers or mechanistic theories. The population was specific, and individual medical decisions require patient-level assessment.
FLOW: exploring kidney outcomes
In the FLOW study, researchers investigated semaglutide among people with type 2 diabetes and chronic kidney disease. The trial evaluated a combination of serious kidney outcomes and death from kidney or cardiovascular causes. Its 2024 report described a lower risk of the primary composite outcome in the semaglutide group relative to placebo, with a reported hazard ratio of 0.76. This was an encouraging signal from a large outcomes-focused study and a further illustration of how peptide-related medicines are being evaluated against important health endpoints. It is distinct from a claim that any product marketed for kidney protection has been tested, or that treatment is appropriate for every person with kidney disease.
What makes these studies especially persuasive
Across these reports, several design features increase confidence. Researchers enrolled substantial numbers of participants, used randomized treatment assignments, defined comparison groups, and reported endpoints that matter to patients and clinicians. Peer-reviewed publication provides enough information for other scientists to inspect design and analysis choices. Follow-up periods extending many months or years can reveal patterns that a short laboratory study would miss. None of these safeguards means a result is beyond criticism, but together they create a much stronger basis for claims than testimonials. Study participants were also monitored under protocols that should not be confused with unsupervised use.
What positive results cannot tell us
A successful trial establishes evidence about a specific study question. It does not prove that every peptide is effective, that different delivery systems are equivalent, or that an investigational research chemical can replace an authorized medicine. Side effects and discontinuations occurred in these trials, and treatment decisions depend on contraindications, clinical history, access, and the exact licensed product. Comparing percentages across different trials can be misleading because participant populations, design choices, and definitions differ. Likewise, selective reporting of only promising outcomes can exaggerate confidence if readers never see the limitations. The purpose of highlighting these examples is to show what strong evidence looks like, not to minimize unanswered questions.
What comes next in clinical research
Researchers continue to study multi-receptor therapies, new formulations, oral peptide delivery strategies, and peptide medicines targeting indications beyond obesity and diabetes. The field is expanding because the human results from validated compounds have justified further investment and curiosity. Progress will depend on well-controlled trials, transparent reporting of favorable and unfavorable outcomes, and replication across groups of patients. If an experimental peptide becomes a future success story, the evidence should be visible in peer-reviewed reports and regulatory assessments rather than promotional summaries. The encouraging lesson from the trials above is that peptide science can be clinically important when tested rigorously.